Novel Personalized Therapeutic Strategies for Breast Cancer
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 November 2021) | Viewed by 3861
Special Issue Editor
2. Department of Oncology and Hemato-Oncology, University of Milano, 20140 Milan, Italy
Interests: breast cancer; phase I studies; immunotherapy; targeted therapy; precision medicine; NGS
Special Issue Information
Dear Colleagues,
Breast cancer represents the prototype of heterogeneous disease. Over the last 25 years, transcriptomic and genomic studies have revealed that breast cancer encompasses at least three different entities, being characterized by a great heterogeneity with varying levels of chromosomal alterations and somatic mutations. The introduction of high throughput sequencing methodologies has yielded relevant insight into the mutational and immune escape mechanisms underpinning different breast cancers. However, the clinical implementation of biomarker-driven therapeutic approaches in breast cancer still presents several challenges.
Besides anti-HER2 drugs for HER2-positive breast cancer and PARP inhibitors for BRCA-mutated tumors, no other personalized treatment is currently available for other breast cancer subtypes. Nevertheless, immunotherapy-based approaches have provided controversial results so far, with limited activity only observed in PD-L1-positive triple-negative breast cancers. Therefore, the implementation of innovative therapeutic strategies has to be based on a better definition and clinical validation of the molecular and immune mechanisms that characterized breast tumors.
This Special Issue is aimed at summarizing the recent advances in preclinical and early drug developments regarding new treatments for various types of breast cancer, with a special focus on clinical utility and how their implementation will lead to the growing personalization of breast cancer care.
Prof. Dr. Giuseppe Curigliano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- early drug development
- phase I studies
- immunotherapy
- targeted therapy
- precision medicine
